AI in Drug Discovery and Development Market (2025-2033) | GenAI in Pharma, Smart Drug Design, Drug Development Acceleration & Market Forecasting in United States, Japan, Europe, MENA

DataM Intelligence has released a new research report titled "AI in Drug Discovery and Development Market Market Size 2026" The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global AI in Drug Discovery and Development Market market.

Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/ai-in-drug-discovery-and-development-market?kb

United States: Recent Industry Developments
✅ February 2026: IBM Watson Health expanded its AI-driven drug discovery platform to accelerate target identification and clinical trial optimization using advanced machine learning models.
✅ January 2026: Recursion Pharmaceuticals announced new AI-powered drug candidates entering preclinical stages, leveraging high-throughput phenomics and deep learning.
✅ December 2025: Insilico Medicine advanced its AI-designed drug pipeline, achieving faster timelines in small molecule development for oncology indications.

List of Key Players 2026:

Alphabet (Google DeepMind), Atomwise Inc., BenevolentAI, BioMap, BioSymetrics, DEEP Genomics, Euretos, Exscientia, IBM, and Iktos

Growth Forecast Projected 2026:

The Global AI in Drug Discovery and Development Market Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Key Developments 2025-2026:

✅ February 2026: Pharmaceutical companies accelerated the deployment of AI-driven platforms integrating machine learning and natural language processing to enhance target identification, drug design, and clinical decision-making.

✅ January 2026: Technology providers expanded AI solutions with advanced predictive analytics and generative models to optimize molecule screening, trial design, and success rate forecasting.

✅ December 2025: Increased adoption of AI-enabled tools supported real-time data analysis for biomarker discovery, precision medicine, and early-stage drug validation.

✅ November 2025: Organizations strengthened R&D efficiency by leveraging AI for unstructured data processing, improving candidate selection, and reducing drug development timelines.

✅ October 2025: Integration of AI platforms with existing laboratory systems and clinical databases streamlined workflows, enhanced data accuracy, and improved cross-functional collaboration.

How Our Market Research Process Works:

The global AI in Drug Discovery and Development Market Market research report is developed using a comprehensive combination of primary and secondary data sources. The study evaluates a wide range of industry-influencing factors, including government regulations, evolving market dynamics, competitive intensity, and historical performance trends. It also analyzes technological advancements, emerging innovations, and developments across related industries. In addition, the report assesses market volatility, growth opportunities, potential barriers, and key challenges that could impact the future expansion of the AI in Drug Discovery and Development Market ecosystem.

Recent Mergers & Acquisitions (M & A) 2026:

• March 2026 - Schrödinger, Inc. acquired a minority stake in Nimbus Therapeutics AI division for $75 million to accelerate physics-based computational drug discovery platforms

• March 2026 - BioNTech acquired an AI oncology startup (undisclosed) for approximately $200 million to strengthen precision medicine and immunotherapy pipeline

• February 2026 - Exscientia entered a merger agreement with BenevolentAI in a deal valued at over $1 billion to expand end-to-end AI-enabled drug development pipelines

• February 2026 - Atomwise acquired a small-molecule AI startup (undisclosed name) for $80 million to expand deep learning drug screening capabilities

• January 2026 - Insilico Medicine acquired PandaOmics AI platform assets from a private biotech firm to enhance generative AI-based target identification

• January 2026 - Recursion Pharmaceuticals announced acquisition of Cyclica for approximately $150 million to strengthen AI-driven target discovery and multi-parameter optimization capabilities

Request Strategic Market Customization: https://datamintelligence.com/customize/ai-in-drug-discovery-and-development-market?kb

Japan: Recent Industry Developments
✅ February 2026: Takeda Pharmaceutical Company integrated AI platforms to enhance rare disease drug discovery and precision medicine initiatives.
✅ January 2026: Astellas Pharma expanded collaborations with AI biotech firms to improve predictive modeling in early-stage drug development.
✅ December 2025: Daiichi Sankyo utilized AI algorithms to optimize clinical trial design and accelerate oncology drug development pipelines.

Major Focused Key Segmentations 2026:

By Technology: Machine Learning, Natural Language Processing, Generative AI, Others

By Application: Target Discovery & Validation, Hit Discovery & Virtual Screening, Hit-to-Lead, Lead Optimization, Pre-Clinical Testing, Clinical Trials, Others

Regional Growth Analysis for Market:

⇥ North America: Leads the market driven by strong biotech ecosystems, advanced AI adoption, and significant pharmaceutical R&D investments.

⇥ Japan: Shows strong growth supported by innovation in precision medicine, robotics, and government-backed digital healthcare initiatives.

⇥ Asia-Pacific (excluding Japan): Rapidly expanding due to increasing clinical trials, AI integration in drug research, and growing pharma manufacturing in China and India.

⇥ Europe: Advancing steadily with strong regulatory frameworks, collaborative research, and rising AI adoption in drug development.

⇥ Middle East & Africa: Emerging region supported by digital transformation in healthcare and growing investments in life sciences research.

We Provide Benefits of the Report:

Chapter 1: Lays the foundation by defining the scope of the report, highlighting core market segments across regions, product types, and applications. It delivers a clear snapshot of current market size, growth potential, and how the industry is expected to evolve in both the near and long term.

Chapter 2: Spotlights the most impactful market insights, unveiling the transformative trends and forces shaping the future of the industry.

Chapter 3: Provides a deep dive into the competitive landscape of , covering revenue shares, strategic initiatives, and notable mergers & acquisitions that are reshaping the market.

Chapter 4: Presents detailed company profiles of leading players featuring financial performance, product portfolios, profit margins, and key milestones that set them apart in the industry.

Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets.

Chapter 7: Analyzes the market by product type, spotlighting segment-specific opportunities and helping stakeholders identify untapped, high-growth areas.

Chapter 8 :Explores the market through application-based segmentation, assessing demand across industries and pinpointing downstream sectors with the strongest potential for growth.

Chapter 9: Maps the industry's supply chain in detail, tracing upstream and downstream activities to provide clarity on value creation across the ecosystem.

Chapter 10: Wraps up with a concise summary of the report's key insights distilling the most critical findings and strategic takeaways for decision-makers and stakeholders.

Unlock Full 360° Strategic Report: https://www.datamintelligence.com/buy-now-page?report=ai-in-drug-discovery-and-development-market?kb

FAQ

Q1: What is the current size of the AI in Drug Discovery and Development Market Market?

A: The AI in Drug Discovery and Development Market Market was valued at US$ 6.24 billion in 2024 and is forecasted to hit US$ 34.05 billion by 2033

Q2: How rapidly will the Market expanding?

A: The AI in Drug Discovery and Development Market market is projected to grow at a CAGR of 18.5% between 2025 and 2033.

Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.